dr. M.H.J. (Marloes) Hagens

Promotieonderzoek aan het MS Centrum Amsterdam UMC

R Geraldes, M Juryńczyk, G dos Passos, A Pichler, K Chung, M Hagens, S Ruggieri, E Huerga, M Jorda, C Enzhinger, D Chard, F Barkhof, C Gasperini, A Rovira, G DeLuca, J Palace, on behalf of the MAGNIMS study group. Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2020 Apr; 91(4) :388-391

MHJ Hagens, SV Golla, B Janssen, DJ Vugts, W Beaino, AD Windhorst, J O’Brien-Brown, M Kassiou, RC Schuit, LA Schwarte, HE de Vries, J Killestein, F Barkhof, BNM van Berckel and AA Lammertsma. The P2X₇ receptor tracer [¹¹C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first in man study. European Journal of Nuclear Medicine and Molecular Imaging. 2020 Feb; 47:s379–389

S Collorone, F Prados, MHJ Hagens, C Tur, B Kanber, CH Sudre, C Lukas, C Gasperini, C Oreja-Guevara, M Andelova, O Ciccarelli, MP Wattjes, S Ourselin, DR Altmann, BM Tijms, F Barkhof, AT Toosy, for the MAGNIMS Study Group. Single-subject structural cortical networks in clinically isolated syndrome. Multiple Sclerosis Journal. ePub 2019 Jul

I Dekker, CE Leurs, MHJ Hagens, ZLE van Kempen, BI Lissenberg/Witte, F Barkhof, BMJ Uitdehaag, LJ Balk, MP Wattjes and J Killestein. Predicting disease activity and disability progression in RRMS patients on natalizumab.  Multiple Sclerosis and Related Disorders. 2019 May; 33:82-87

MHJ Hagens, SV Golla, M Wijburg, M Yaqub,  D Heijtel, MD Steenwijk, P Schober, J Brevé, RC Schuit, TA Reekie, M Kassiou, AM van Dam, AD Windhorst, J Killestein, F Barkhof, M Yaqub, BNM van Berckel and AA Lammertsma. In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [¹⁸F]DPA714 PET. Journal of Neuroinflammation. 2018 Nov; 15(1):314

MHJ Hagens, J Burggraaff, ID Kilsdonk, ML de Vos, N Cawley, E Sbardella, M Andelova, M Amann, P Pantano, BI Lissenberg-Witte, J Killestein, C Oreja-Guevara, O Ciccarelli, C Gasperini, C Lukas, MP Wattjes, F Barkhof, for the MAGNIMS study group. 3 Tesla MRI does not Improve the Diagnosis of Multiple Sclerosis - a Multicenter Study. Neurology. 2018 Jul; 91(3):e249-e257

M Filippi, P Preziosa, A Meani, O Ciccarelli, S Mesaros, A Rovira, J Frederiksen, C Enzinger, F Barkhof, C Gasperini, W Brownlee, J Drulovic, X Montalban, S Cramer, A Pichler, M Hagens, S Ruggieri, V Martinelli, K Miszkiel, M Tintorè, G Comi, I Dekker, B Uitdehaag, I Dujmovic, M Rocca. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology. 2018 Feb; 17(2):133-142

MHJ Hagens, J Burggraaff, ID Kilsdonk, S Ruggieri, S Collorone, R Cortese, N Cawley, E Sbardella, M Andelova, M Amann, JM Lieb, P Pantano, BI Lissenberg-Witte, J Killestein, C Oreja-Guevara, J Wuerfel, O Ciccarelli, C Gasperini, C Lukas, A Rovira, F Barkhof, MP Wattjes, for the MAGNIMS study group. Impact of 3 Tesla MRI on Interobserver Agreement in Clinically Isolated Syndrome: A MAGNIMS Multicentre Study. Multiple Sclerosis Journal. 2019 Mar; 25(3):352–360

MHJ Hagens, J Killestein, MM Yaqub, GAMS van Dongen, AA Lammertsma, F Barkhof and BNM van Berckel. Cerebral rituximab uptake in multiple sclerosis: a ⁸⁹Zr-immunoPET pilot study. Multiple Sclerosis Journal. 2018 Apr; 24(4):543-545.

MHJ Hagens, BNM van Berckel and F Barkhof. Novel MRI and PET markers of neuroinflammation in multiple sclerosis. Current Opinion in Neurology. 2016 Jun; 29(3):229-36

MHJ Hagens, ELJ Hoogervorst, STFM Frequin, SC Tromp. Cerebrospinal Venous Outflow in Multiple Sclerosis Patients versus Fatigue and/or Depression. Interventional Neurology. 2014 Aug; 2(4):193-200